Orasis Pharmaceuticals

Executive Summary

Orasis Pharmaceuticals is an Israeli ophthalmic biotech company that has developed Qlosi™ (0.4% pilocarpine HCL ophthalmic solution) for the treatment of presbyopia, a condition affecting nearly two billion people globally. As a non-invasive pharmacologic alternative to glasses or surgery, Qlosi offers a novel eye drop that temporarily improves near vision. The company recently achieved commercial stage status with FDA approval in 2024, positioning it to capture a significant share of the large presbyopia market. Orasis leverages its expertise in ocular pharmacology to address the high unmet need for convenient presbyopia solutions. With a targeted sales force and strategic marketing, the company is poised to drive adoption among eye care professionals and patients. Orasis is well-capitalized to execute its launch plan, and early prescription trends indicate strong interest. The company's future growth depends on expanding market access, building brand awareness, and potentially pursuing label expansions or additional indications. Overall, Orasis represents a promising investment in the ophthalmic space with a first-mover advantage in a multi-billion-dollar market.

Upcoming Catalysts (preview)

• Q4 2026Qlosi sales revenue milestone (first full-year post-launch)80% success
• Q3 2026Potential European (EMA) approval for presbyopia60% success
• Q1 2027Label expansion into pediatric myopia or other indications40% success